1. Scrip
  2. >>Business

Gilead Licensing Deal Expands Remdesivir Access, Capacity

Mylan, Cipla, Hetero Labs, Jubilant, Ferozsons Labs Get Rights

 
• By Vibha Ravi

Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.

Licensing Pacts Should Address Access and Pricing Concerns • Source: Shutterstock

Killing two birds with one stone, Gilead Sciences Inc. has granted non-exclusive licenses for remdesivir to Mylan NV, Cipla Ltd., Jubilant Life Sciences Ltd., Hetero Drugs Ltd. and Ferozsons Laboratories Ltd. for 127 developing countries, including several from Asia but excluding China, thus tilting the pricing debate in its favor while creating substantial capacity for its production.

The investigational drug is currently at the forefront of the fight against COVID-19, with the US having granted Emergency Use...

More from Business

More from Scrip

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.